Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Polycythemia Vera 6Thrombocythemia, Essential 5Carcinoma, Hepatocellular 4Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Philadelphia Chromosome 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Leukemia 2Hepatitis C, Chronic 2Carcinoma, Squamous Cell 2Skin Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm, Residual 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Influenza, Human 1Infections 1Hepatitis C 1Hepatitis B, Chronic 1Hemangiosarcoma 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Blast Crisis 1

Interventions

Influenza Vaccines 15Vaccines 2Oseltamivir 2Cyclophosphamide 2ziprasidone 1vaxigrip 1trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine 1thymoglobulin 1peginterferon alfa-2a 1influvac 1fludarabine 1baloxavir 1Zolpidem 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Tobramycin 1Starch 1Spironolactone 1Sevelamer 1SARS-CoV-2 inactivated vaccines 1Rocuronium 1Rituximab 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nivolumab 1Nifedipine 1Nafcillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Influenza, Human × peginterferon alfa-2a × Clear all
NCT00962715 2012-08-03

Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Influenza, Human, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡